Addiction neuroscience · 2025
Corticotrophin-releasing hormone binding protein in the basolateral amygdala: divergent roles in cocaine and opioid addiction like behaviors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wood Courtney P, Gurha Arnav, Crook Caitlin, Martinez Angelica, Dirik Selen, Moreno Cloe, Vaiyapuri Anirudh, Libster Avraham, Telese Francesca, de Guglielmo Giordano
Аннотация
PURPOSE: Meningitis and encephalitis are medical emergencies requiring prompt intervention. The BioFire Meningitis/Encephalitis (M/E) panel (BioFire® Diagnostics, Salt Lake City, UT) is approved by the U.S. Food and Drug Administration (FDA) for the detection of 14 pathogens directly on cerebrospinal fluid (CSF). Impact of the M/E panel on antiviral and viral tests use has been evaluated in a several patient populations but data in cancer patients remain limited. In this study, we evaluated the impact of the M/E panel within a year of its implementation on both acyclovir and singleplex viral PCR test utilization in a cancer patient population.
METHODS: This was a pre- and post-intervention study. Data from patients tested in the year prior to the intervention and one year following the intervention were extracted from the laboratory and clinical information systems.
RESULTS: A total of 476 patients (207 pre-intervention and 269 post-intervention) were tested during the study period. In the post-intervention period, the number of targeted viral tests was reduced by 64.9 % (703 to 247 PCRs), and the total number of patients treated with acyclovir was reduced by 29.1 % (82 patients vs 45 patients) with a reduction in the duration of therapy from 7.33 days to 4.47 days in the post-intervention period (p < 0.0274).
CONCLUSION: The implementation of the M/E panel contributed to a reduction in the number of singleplex PCR tests performed and a reduction in the utilization and duration of acyclovir therapy in our cancer patient population.
METHODS: This was a pre- and post-intervention study. Data from patients tested in the year prior to the intervention and one year following the intervention were extracted from the laboratory and clinical information systems.
RESULTS: A total of 476 patients (207 pre-intervention and 269 post-intervention) were tested during the study period. In the post-intervention period, the number of targeted viral tests was reduced by 64.9 % (703 to 247 PCRs), and the total number of patients treated with acyclovir was reduced by 29.1 % (82 patients vs 45 patients) with a reduction in the duration of therapy from 7.33 days to 4.47 days in the post-intervention period (p < 0.0274).
CONCLUSION: The implementation of the M/E panel contributed to a reduction in the number of singleplex PCR tests performed and a reduction in the utilization and duration of acyclovir therapy in our cancer patient population.